Vibrant Therapeutics

Executive Summary

Vibrant Therapeutics is a preclinical-stage biotechnology company pioneering personalized and off-the-shelf cancer vaccines and immunotherapies. Leveraging a proprietary platform designed to induce robust, durable T-cell responses, the company aims to address a wide range of solid tumors by harnessing the patient's own immune system. Founded in 2021 and headquartered in San Francisco, Vibrant has raised $61 million in funding to advance its pipeline, which includes both personalized neoantigen vaccines and universal 'off-the-shelf' candidates targeting shared tumor antigens. The company's approach combines advanced computational antigen prediction with novel delivery technologies to enhance immunogenicity and overcome tumor immune evasion, setting it apart in the competitive immuno-oncology landscape.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead personalized vaccine candidate60% success
• Q1 2027Initiation of first-in-human Phase 1 trial for off-the-shelf vaccine55% success
• Q3 2026Presentation of preclinical proof-of-concept data at major oncology conference70% success